



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Non-treatment of preoperative anaemia is substandard clinical practice

Spahn, D R ; Zacharowski, K

DOI: <https://doi.org/10.1093/bja/aev099>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-114409>

Journal Article

Published Version

Originally published at:

Spahn, D R; Zacharowski, K (2015). Non-treatment of preoperative anaemia is substandard clinical practice. *British Journal of Anaesthesia*, 115(1):1-3.

DOI: <https://doi.org/10.1093/bja/aev099>

EDITORIALS

Non-treatment of preoperative anaemia is substandard clinical practice

D. R. Spahn^{1,*} and K. Zacharowski²

¹ University of Zürich and University Hospital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland, and

² Department of Anaesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany

*Corresponding author. E-mail: donat.spahn@usz.ch

It is well known that preoperative anaemia is frequent and associated with increased mortality and morbidity, even if only mild anaemia is present.^{1,2} In addition, preoperative anaemia is one of the most significant risk factors in subsequent red blood cell transfusion,³ which in itself has adverse effects on mortality and morbidity.⁴ Therefore, unmanaged preoperative anaemia is a contraindication for elective surgery.⁴

In this edition of the *British Journal of Anaesthesia*, Muñoz and colleagues⁵ rightly alerted the medical community, reporting that preoperative anaemia is often left untreated. The paradox of known negative consequences of untreated anaemia and current practice is explained by the presentation of 10 widely held misconceptions. Moreover, we identified two additional reasons why physicians are still hesitating to treat preoperative anaemia systematically. First, the World Health Organization's definition of anaemia with a haemoglobin concentration of <120 g litre⁻¹ in women and <130 g litre⁻¹ in men is not sufficiently known by the majority of physicians. Furthermore, the notion that very mild forms of anaemia (haemoglobin values between 100–120 and 100–130 g litre⁻¹, respectively) result in adverse clinical outcomes, such as increased mortality and a long list of complications,^{1,2} is also not well known. Second, there may be reluctance by some physicians to treat preoperative anaemia actively, because of the fact that they themselves will be held responsible for any adverse events occurring thereafter. In contrast, a perioperative transfusion in a patient who is anaemic before surgery is considered by most an inevitable event, for which medical staff cannot be held responsible. Therefore, some physicians prefer not to be involved in treating

preoperative anaemia. We hope that the refuting by Muñoz and colleagues⁵ of 10 widely held misconceptions helps pave the way to widespread treatment of preoperative anaemia.

A consortium of four large German University Hospitals (Frankfurt, Münster, Bonn, and Kiel) is engaged in the concept of patient blood management (PBM). The Frankfurt group has shown how to target and implement treatment of preoperative anaemia (ClinicalTrials.gov Identifiers: NCT01820949 and NCT02147795). Their investigation clearly highlights five key success factors (Table 1) for implementing a comprehensive preoperative anaemia treatment programme. The first factor, which is clearly the most important, was establishing a dedicated interdisciplinary PBM steering committee, with preoperative anaemia treatment being the first pillar of PBM.⁴ Second, the inclusion and support of senior hospital management is of utmost importance. Only with this support can the necessary reorganization of the preclinical procedures and structures be implemented. Additionally, the understanding of surgical and medical disciplines is crucial to the management and treatment of preoperative anaemia. Last, but not least, focusing our efforts on the knowledge of how operations are regularly performed in anaemic patients, who frequently require allogeneic red blood cell transfusions, is also essential (www.patientbloodmanagement.eu). Such favourable hospital conditions and improvements can be achieved only by continuous education over years and through the coordination of a dedicated interdisciplinary PBM steering committee. Should your hospital not yet have the aforementioned structure, then becoming a leader in PBM and establishing a steering committee is the way forwards.

Table 1 Key success factors for the large-scale implementation of preoperative anaemia treatment

1. Dedicated, interdisciplinary patient blood management steering committee
2. Support from senior hospital management
3. Commitment from surgical and medical disciplines
4. Knowledge of patient blood management background (anaemia, transfusion, alternatives to transfusion)
5. Knowledge of clinical and preclinical management:
 - Surgical procedures associated with frequent preoperative anaemia and considerable blood loss
 - Structure and processes of preclinical evaluation to be reorganized and optimized

Other centres have also succeeded in implementing treatment of preoperative anaemia. Theusinger and colleagues⁶ contacted the primary physician of each patient found to be anaemic before surgery. These patients were to undergo major orthopaedic surgery ($n=8871$), with suggested treatment of anaemia using erythropoietin α , i.v. iron, vitamin B₁₂ and folic acid. Despite the fact that not all patients who were anaemic before surgery were treated, the incidence of anaemia on the day of operation decreased from 15 to 10% ($P<0.01$) and total allogeneic transfusion rate reduced from 20 to 10% ($P<0.01$). Short-term treatment of preoperative anaemia with erythropoietin and i.v. iron has also been shown to be successful in orthopaedic⁷ and cardiac surgery.⁸ Likewise, a group of four Spanish hospitals recently published their success in short-term preoperative treatment of anaemia with erythropoietin and i.v. iron in 2547 patients undergoing hip and knee arthroplasty or surgery for hip fracture.⁹ They could decrease the allogeneic transfusion rate from 37 to 24% ($P<0.01$), the postoperative infection rate from 12 to 8% ($P<0.01$), and the length of hospital stay from 12 to 11 days ($P<0.01$). In patients undergoing surgery for hip fracture, the 30 day mortality was reduced from 9 to 5% ($P<0.01$).

Through sound scientific evidence, they disproved 10 misconceptions of perioperative anaemia treatment. Moreover, this medical need can be met with successful treatment options. Therefore, we conclude that there is no reason why treatment of preoperative anaemia should not be widely practised. Untreated preoperative anaemia is indeed a contraindication for elective surgery, and failure to treat preoperative anaemia is substandard clinical practice.

Declaration of interest

D.R.S.'s academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland; the Ministry of Health (Gesundheitsdirektion) of the Canton of Zurich, Switzerland for Highly Specialized Medicine; the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland; the Swiss Foundation for Anesthesia Research, Zurich, Switzerland; Bundesprogramm Chancengleichheit, Berne, Switzerland; CSL Behring, Berne, Switzerland; and Vifor SA, Villars-sur-Glâne, Switzerland.

D.R.S. was the chairman of the ABC Faculty and is the co-chairman of the ABC-Trauma Faculty, both of which are managed by Physicians World Europe GmbH, Mannheim, Germany and sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland; CSL Behring

GmbH, Marburg, Germany; and LFB Biomédicaments, Courtaubeouf Cedex, France.

In the past 5 years, D.R.S. has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland; AMGEN GmbH, Munich, Germany; AstraZeneca AG, Zug, Switzerland; Bayer (Schweiz) AG, Zürich, Switzerland; Baxter AG, Volketswil, Switzerland; Baxter S.p.A., Roma, Italy; B. Braun Melsungen AG, Melsungen, Germany; BoehringerIngelheim (Schweiz) GmbH, Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland; CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland; Curacyte AG, Munich, Germany; Ethicon Biosurgery, Sommerville, NJ, USA, Fresenius SE, Bad Homburg v.d.H., Germany; Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland); GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany; Janssen-Cilag AG, Baar, Switzerland; Janssen-Cilag EMEA, Beerse, Belgium; Merck Sharp & Dohme AG, Luzern, Switzerland; Novo Nordisk A/S, Bagsvård, Denmark; Octapharma AG, Lachen, Switzerland; Organon AG, Pfäffikon/SZ, Switzerland; Oxygen Biotherapeutics, Costa Mesa, CA, USA; Photonics Healthcare GmbH, Munich, Germany; ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria; Roche Diagnostics International Ltd, Reinach, Switzerland; Roche Pharma (Schweiz) AG, Reinach, Switzerland; Schering-Plough International, Inc., Kenilworth, NJ, USA; Tem International GmbH, Munich, Germany; Verum Diagnostica GmbH, Munich, Germany; ViforPharma Deutschland GmbH, Munich, Germany; ViforPharma Österreich GmbH, Vienna, Austria; and Vifor (International) AG, St Gallen, Switzerland.

K.Z.'s department is receiving unrestricted educational grants from B. Braun Melsungen AG, Fresenius Kabi GmbH, CSL Behring GmbH, and ViforPharma GmbH.

In the past 3 years, K.Z. has received honoraria or travel support for consulting or lecturing from the following companies: Abbott GmbH & Co. KG, Aesculap Akademie GmbH, AQAI GmbH, Astellas Pharma GmbH, AstraZeneca GmbH, Aventis Pharma GmbH, B. Braun Melsungen AG, Baxter Deutschland GmbH, Biosyn GmbH, Biotest AG, Bristol-Myers Squibb GmbH, CSL Behring GmbH, Dr. F. Köhler Chemie GmbH, Dräger Medical GmbH, Essex Pharma GmbH, Fresenius Kabi GmbH, Fresenius Medical Care, Gambro Hospal GmbH, Gilead, GlaxoSmithKline GmbH, Grünenthal GmbH, Hamilton Medical AG, HCCM Consulting GmbH, Heinen+Löwenstein GmbH, Janssen-Cilag GmbH, med Update GmbH, Medivance EU B.V., MSD Sharp&Dohme GmbH, Novartis Pharma GmbH, Novo Nordisk Pharma GmbH, P. J. Dahlhausen & Co. GmbH, Pfizer Pharma GmbH, Pulsion Medical Systems S.E., Siemens Healthcare, Teflex Medical GmbH, Teva GmbH, TopMed Medizintechnik GmbH, Verathon Medical, and ViforPharma GmbH.

References

1. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet* 2011; **378**: 1396–407
2. Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. *Br J Anaesth* 2014; **113**: 416–23
3. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. *Transfusion* 2007; **47**: 1468–80
4. Spahn DR, Goodnough LT. Alternatives to blood transfusion. *Lancet* 2013; **381**: 1855–65

5. Muñoz M, Gómez-Ramírez S, Kozek-Langenecker S, et al. 'Fit to fly': overcoming the barriers to preoperative haemoglobin optimization in surgical patients. *Br J Anaesth* 2015; **115**: 15–24
6. Theusinger OM, Kind SL, Seifert B, Borgeat L, Gerber C, Spahn DR. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. *Blood Transfus* 2014; **12**: 195–203
7. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. *Transfusion* 2011; **51**: 118–24
8. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. *Anesthesiology* 2011; **115**: 929–37
9. Muñoz M, Gómez-Ramírez S, Cuenca J, et al. Very-short-term perioperative intravenous iron administration and post-operative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. *Transfusion* 2014; **54**: 289–99

British Journal of Anaesthesia **115** (1): 3–5 (2015)
doi:10.1093/bja/aev155

Early cryoprecipitate for trauma patients is feasible, but will it improve outcome?

B. S. Sachais and B. H. Shaz*

New York Blood Center, 310 East 67th Street, New York, NY 10065, USA

*Corresponding author. E-mail: bshaz@nybloodcenter.org

In this issue of *BJA*, Curry and colleagues¹ demonstrate the feasibility of administering cryoprecipitate as a fibrinogen source within 90 min of admission of trauma patients. This study is important because cryoprecipitate contains fibrinogen and fibronectin, which are critical to clotting; data are variable on the need for cryoprecipitate in trauma patients, and no randomized controlled trials looking at the administration of fibrinogen concentrate or cryoprecipitate in trauma patients have been performed. However, the completion of the randomized clinical trial on the early use of cryoprecipitate is needed before implementation of this practice. Trauma patients receive plasma, which also contains fibrinogen and fibronectin, but at lower amounts and not in therapeutic doses. In some countries, prothrombin complex concentrates are used, which contain some but not all of the clotting factors. Also, fibrinogen concentrates are being used in trauma patients and require less volume for administration.

Fibrinogen (factor I) is a 340 kDa protein comprised of two sets of disulfide-bridged α , β and γ chains. Thrombin cleavage of fibrinopeptide A from the α chains creates fibrin, which polymerizes and forms the proteinaceous structural basis for blood clots.² As such, maintaining adequate fibrinogen concentrations in bleeding patients seems to be a rational objective. However, our understanding of what constitutes an adequate concentration in a bleeding patient, how to determine fibrinogen concentrations rapidly and meaningfully, and what products to use for replacement is relatively poor.^{3–4} A 2013 review in the Cochrane Collaboration examining the use of fibrinogen concentrates in bleeding patients found only six randomized controlled trials (248 subjects), of which two had mortality data.⁵ While they concluded that there was a suggestion of benefit on reduction of red blood cell (RBC) transfusions, the authors were unable to draw any conclusions on mortality. Interestingly, the studies reviewed showed no effect on other outcomes, including thrombotic adverse events. A systematic review of fibrinogen concentrate in

trauma revealed 12 articles, including a single prospective study.⁶ Again, conclusions by the authors were limited, but suggested a reduction in the use of RBC transfusions in this setting. Taken together, these studies suggest that administration of fibrinogen may result in earlier haemorrhage control.

Given that 40% of trauma-related mortality is attributable to uncontrolled bleeding, a deeper understanding and optimization of fibrinogen supplementation is of great interest. There has been a substantial focus on the early administration of plasma and platelets (plasma:platelet:RBC transfusion ratio); a ratio of 1:1:1 compared with 1:1:2 did not demonstrate improved survival, but showed that more plasma and platelets help to achieve earlier haemostasis (although there was no decrease in the use of RBC transfusions within the two groups).⁷ However, cryoprecipitate has not been as well studied. Indeed, fibrinogen deficiency (as defined by concentrations below 100 mg dL⁻¹) develops early in trauma.⁸ The lower amount of fibrinogen administration via blood products, including whole blood, plasma, and cryoprecipitate, and defined as fibrinogen:RBC ratio has been associated with higher mortality in military trauma,⁹ a lower cryoprecipitate:RBC ratio has been associated with higher mortality in civilian trauma,¹⁰ and data from an observational cohort study relates low fibrinogen at admission to higher trauma mortality at 24 h and 28 days.¹¹ These studies indicate that increasing fibrinogen concentrations in trauma patients may be beneficial. However, there are no randomized trials looking specifically at fibrinogen or cryoprecipitate in trauma patients. It is from this perspective that the study by Curry and colleagues,¹ published in this issue of the *BJA*, takes on importance.

In their study, Curry and colleagues¹ performed a feasibility study to determine whether it is possible to administer cryoprecipitate as a fibrinogen source within 90 min of admission of trauma patients. This is operationally complex because cryoprecipitate must be thawed and then delivered and cannot be stored for more than 6 h. Secondary objectives included laboratory